<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297293</url>
  </required_header>
  <id_info>
    <org_study_id>B-2002/594-003</org_study_id>
    <nct_id>NCT04297293</nct_id>
  </id_info>
  <brief_title>Ramosetron OD Tablet and Postdischarge Nausea and Vomiting</brief_title>
  <official_title>Effects of Ramosetron Orally Disintegrating Tablet on the Prophylaxis of Postdischarge Nausea and Vomiting in High-risk Patients Undergoing Day Surgery Under General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative nausea and vomiting after general anesthesia is one of the common anesthetic
      complications. If the patient is discharged from the hospital after surgery, proper treatment
      may be delayed or impossible if nausea and vomiting occurred. Thus, it is necessary to
      prevent these symptoms beforehand. Patients who underwent day-surgery will be treated with
      prophylactic ramosetron orally disintegrating tablets to determine whether the frequency of
      nausea and vomiting is decreased when the patient returned home after discharge.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in the occurrence of postoperative nausea</measure>
    <time_frame>Postoperative 30 minute, 3 hour, 24 hour, and 48 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in the occurrence of postoperative vomiting</measure>
    <time_frame>Postoperative 30 minute, 3 hour, 24 hour, and 48 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in the severity of postoperative nausea</measure>
    <time_frame>Postoperative 30 minute, 3 hour, 24 hour, and 48 hour</time_frame>
    <description>Numerical rating scale range from 0 to 100 (0 = no pain, 100 = the most severe pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of patient's satisfaction score</measure>
    <time_frame>Postoperative 30 minute, 3 hour, 24 hour, and 48 hour</time_frame>
    <description>Numerical rating scale range from 0 to 100 (0 = no pain, 100 = the most severe pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the number of postoperative administration of rescue antiemetic drug</measure>
    <time_frame>Postoperative 30 minute, 3 hour, 24 hour, and 48 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Day Surgery</condition>
  <arm_group>
    <arm_group_label>Ramosetron-ODT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramosetron</intervention_name>
    <description>Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)</description>
    <arm_group_label>Ramosetron-ODT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who undergo day-surgery under general anesthesia and are discharged on the
             day of surgery

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  Patients who are taking other serotonin receptor antagonists

          -  Patients who have galactose intolerance or Lapp lactase deficiency

          -  patients who have glucose-galactose malabsorption
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun-Jung Shin, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-Jung Shin, MD., PhD.</last_name>
    <phone>82317877499</phone>
    <email>hjshin.anesth@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Hyun-Jung Shin, Ph.D., M.D.</last_name>
      <phone>82317877499</phone>
      <email>hjshin.anesth@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyun-Jung Shin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

